Systematic Review

Global Prevalence of Colistin Resistance in Klebsiella pneumoniae from Bloodstream Infection: A Systematic Review and Meta-Analysis

Leonard Ighodalo Uzairue 1,2,*, Ali A. Rabaan 3,4,5, Fumilayo A. Adewumi 6, Obiageli J. Okolie 7, Jamiu B. Folorunso 8, Muhammed A. Bakhrebah 9, Mohammed Garout 10, Wadha A. Aloufan 11,12, Muhammad A. Halwani 13, Aref A. Alamri 14, Shaima A. Halawani 15, Abdulkarim Hasan 16,17, Abbas Al Mutair 18,19,20,21, Saad Alhumaid 22, Johnson Etafo 23, Idorenyin Utip 24, Ikenna Maximillian Odoh 25, and Nikoli S. Uwaezuoke 26

1 Department of Medical Laboratory Science, Faculty of Basic Medical Science, Federal University, Oye-Ekiti 371104, Ekiti State, Nigeria
2 Department of Microbiology, College of Bioscience, Federal University of Agriculture, Abeokuta 112101, Ogun State, Nigeria
3 Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia
4 College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia
5 Department of Public Health and Nutrition, The University of Haripur, Haripur 22610, Pakistan
6 Department of Medical Microbiology, College of Medicine, Ekiti State University, Ado-Ekiti 362103, Ekiti State, Nigeria
7 Department of Applied Sciences, University of West England, Bristol BS16 1QY, UK
8 Medical Microbiology Unit, Department of Medical Laboratory, Directorate of Health Services, Olatbisi Onibio University, Ago-Iwoye 120107, Ogun State, Nigeria
9 Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia
10 Department of Community Medicine and Health Care for Pilgrims, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia
11 Department of Microbiology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait
12 Microbiology Unit, Department of Laboratories, Farwania Hospital, Farwania 85000, Kuwait
13 Department of Medical Microbiology, Faculty of Medicine, Al Baha University, Al Baha 4781, Saudi Arabia
14 Department of Molecular Microbiology and Cytogenetics, Riyadh Regional Laboratory, Riyadh 11425, Saudi Arabia
15 Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, King Saud University and King Saud University Medical City, Riyadh 11451, Saudi Arabia
16 Department of Pathology, Faculty of Medicine, Al-Azhar University, Cairo 11884, Egypt
17 Prince Mishari Bin Saud Hospital in Baljurashi, Ministry of Health, Baljurash 22888, Saudi Arabia
18 Research Center, Almoosa Specialist Hospital, Al-Ahsa 36342, Saudi Arabia
19 College of Nursing, Princess Norah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia
20 School of Nursing, Wollongong University, Wollongong, NSW 2522, Australia
21 Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran 33048, Saudi Arabia
22 Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Al-Ahsa 31982, Saudi Arabia
23 Department of Medical Microbiology, Medical Federal Centre, Owo 341105, Ondo State, Nigeria
24 School of Medical and Health Sciences, Bangor University, Bangor LL57 2EF, UK
25 University Medical Centre, Federal University, Oye-Ekiti 371104, Ekiti State, Nigeria
26 Department of Medical Microbiology, Medical Federal Centre, Abuja 310001, Federal Capital Territory, Nigeria
* Correspondence: leonard.uzairue@fuoye.edu.ng

Abstract: Background: Among gram-negative bacteria, Klebsiella pneumoniae is one of the most common causes of healthcare-related infection. Bloodstream infections (BSIs) caused by Klebsiella pneumoniae are notorious for being difficult to treat due to resistance to commonly used antimicrobials. Klebsiella pneumoniae isolates from bloodstream infections are becoming increasingly resistant to carbapenems. In the fight against carbapenem-resistant Klebsiella pneumoniae, colistin [polymyxin E] is the antimicrobial of choice and is thus widely used. Objective: This study aimed to determine the global prevalence of colistin resistance amongst Klebsiella pneumoniae isolates from bloodstream infections. Methods: PubMed, Medline, Scopus, and the Cochrane Library were searched for published articles without restricting the search period. Studies meeting the predefined inclusion and
exclusion criteria were included, and quality was assessed using Joanna Briggs Institute Checklist. We used a statistical random effect model to analyze data with substantial heterogeneity (I² > 50%) in the meta-analysis. **Results:** A total of 10 studies out of 2873 search results that met the inclusion criteria were included in the final synthesis for this study. A pooled prevalence of colistin resistance was 3.1%, 95% CI (1.5–4.7%). The highest colistin resistance pooled prevalence was recorded in isolates studied in 2020 and beyond 12.90% (4/31), while *Klebsiella pneumoniae* isolates studied in 2015 and before and in 2016–2019 showed a pooled colistin resistance rate of 2.89% (48/1661) and 2.95% (28/948), respectively. The highest colistin resistance was found in *Klebsiella pneumoniae* isolates from Thailand (19.2%), while the least pooled resistance was in *Klebsiella pneumoniae* from South Korea (0.8%). The pooled prevalence of the multidrug-resistant (MDR) of *Klebsiella pneumoniae* from bloodstream infection ranged from 80.1%, 95% CI (65.0–95.2%), and the resistance prevalence of other antibiotics by *Klebsiella pneumoniae* from bloodstream infections were as follows; ciprofloxacin (45.3%), ertapenem (44.4%), meropenem (36.1%), imipenem (35.2%), gentamicin (33.3%), amikacin (25.4%) and tigecycline (5.1%). *Klebsiella pneumoniae* recovered from the intensive care unit (ICU) showed higher colistin resistance, 11.5% (9/781%), while non-ICU patients showed 3.03% (80/2604) pooled colistin resistance. **Conclusion:** This study showed low colistin resistance in *Klebsiella pneumoniae* isolates from global bloodstream infections. However, significant colistin resistance was observed in isolates collected from 2020 and beyond. Significant colistin resistance was also observed in *Klebsiella pneumoniae* isolates in bloodstream infections from the intensive care unit (ICU) compared to those from non-ICUs. As a result, there is a need to institute colistin administration stewardship in the ICU in clinical settings.

**Keywords:** colistin-resistance; *Klebsiella pneumoniae*; bloodstream infection; multi-drug resistance; prevalence

---

1. **Introduction**

Multi-drug resistant (MDR) gram-negative bacteria are becoming more widespread around the globe, which presents an increasing risk to human health [1]. Nosocomial *Klebsiella pneumoniae* is responsible for one-third of all gram-negative infections and is associated with carbapenem resistance worldwide [2,3]. These infections include urinary tract infections (UTIs), pneumonia, meningitis, and bloodstream infections. Extended-resistant *Klebsiella pneumoniae* isolates are resistant to carbapenems, fluoroquinolones, aminoglycosides, and cephalosporins. Studies by Dixit et al. [4] and Gandra et al. [5] demonstrated an increase in carbapenem-resistant *Klebsiella pneumoniae* isolates from 29% in 2008 to 57% in 2016. Azam et al. [6] stated that an increase in the carbapenem-resistant *Klebsiella pneumoniae* decreased the number of treatment choices available for potentially fatal infections. A study in Italy in 2013 showed a 43% colistin resistance from carbapenem-resistant isolates collected from 21 hospitals in the study area. It was therefore asserted by the author that there is a possible evolution of colistin resistance in a setting with high *Klebsiella pneumoniae* carbapenemase-producing *Klebsiella pneumoniae* [7].

Bloodstream infections caused by colistin-resistant (CoR) *Klebsiella pneumoniae* (Kp) strains are a cause for concern due to the potential for complications, poor clinical outcomes, and limited treatment options [8,9]. The Polymyxins (colistin and polymyxin B) have made a comeback as a treatment option for infections caused by carbapenem-resistant *Klebsiella pneumoniae* since there are very few new antimicrobials in the pipeline [10,11]. Colistin-resistant *Klebsiella pneumoniae* has a high degree of genetic plasticity; polymyxin resistance may be conferred by a point mutation and a genetic disruption in two-component regulatory systems (TCRS), including pmrAB and phoPQ [12,13].

Polymyxins are the most widely used antimicrobials in the fight against carbapenem-resistant *Klebsiella pneumoniae* [11]. The recent discovery of colistin-resistant *Klebsiella pneumoniae* isolates is a cause for worry, particularly in light of the limited antibiotic options available and the high death rate associated with these infections [14]. Thus, clinical
microbiology laboratories need to identify colistin resistance to adequately respond and prevent patients from receiving ineffective and potentially nephrotoxic medicine [15]. In the past, most clinical microbiology laboratories utilized disk diffusion to evaluate antibiotics, and recently, there has been a transition from manual antibiotic susceptibility testing (AST) to automated techniques [16]. The disk diffusion method has been found to be inefficient and unreliable for colistin susceptibility testing [17]. This assertion is due to the absence of an established breakpoint for disk diffusion for colistin susceptibility testing. The CLSI and EUCAST advised broth micro-dilution to assess colistin susceptibility due to established breakpoint. However, the breakpoints for most automated AST systems for colistin susceptibility have not been established, hence the disapproval by CLSI and EUCAST on the using automated method for colistin susceptibility [18].

As a result of the findings above, there is a need to determine the prevalence of colistin resistance by *Klebsiella pneumoniae* from bloodstream infections. We therefore conducted a comprehensive review and meta-analysis to assess the prevalence of colistin resistance in *Klebsiella pneumoniae* isolates and their antibiotic resistance patterns.

2. Methods
2.1. Search Strategies and Database Used

The databases PubMed, Medline, Scopus, and the Cochrane Library were searched using the MeSH keywords “*Klebsiella pneumoniae*”, or *Klebsiella* and “Colistin Resistant*”, or “Polymyxin E”, or “drug-resistant*”, or “antimicrobial-resistant*” and “bloodstream infection”, or bacteremia*, or sepsis. There were no date restrictions placed on the searches. Combinations of MeSH words with “*Klebsiella pneumoniae*”, “colistin resistance”, and “antibiotic(s)” were performed. We followed the PRISMA guidelines in the study.

2.2. Eligibility
2.2.1. Inclusion Criteria

L.I.U., F.A.A., and A.H. evaluated the titles and abstracts of the papers separately to choose the full-text articles. Another author (A.A.R.) helped resolve any disputes between the three authors. Any study reporting colistin-resistant *Klebsiella pneumoniae* from bloodstream infections that used standard laboratory methods was included in any original studies published and written in English. Studies were considered eligible if they were primary (original) studies with hospital patients with bloodstream infections and had bacterial isolation reports of *Klebsiella pneumoniae* and colistin resistance and antibiotic susceptibility testing based on criteria established by CLSI and EUCAST for colistin resistance testing used. The method used for colistin susceptibility testing was microdilution, the only recommended method for antibiotic susceptibility testing for colistin [18,19].

2.2.2. Exclusion Criteria

The following studies were excluded: any study with a sample size of *Klebsiella pneumoniae* isolates less than 10 (examples are case reports or case series with less than ten isolates), or secondary analysis of *Klebsiella pneumoniae* isolates already reported. Studies that only showed antibiotic resistance without reporting colistin resistance were excluded from the analysis, or studies that reported colistin susceptibility testing methods other than micro-dilution.

2.3. Data Extraction and Data Collection

Name of the first author, date of publication, number of participants, length of time and location of the study, *Klebsiella pneumoniae* strain identified, and resistance to colistin and other antibiotics were used. Data were collected by three writers (L.I.U., F.A.A., and A.H.), while a fourth writer (A.A.R.) reviewed the data’s validity. Figure 1 shows the flow chart of the literature screening process.
isolates), or secondary analysis of Klebsiella pneumoniae isolates already reported. Studies that only showed antibiotic resistance without reporting colistin resistance were excluded from the analysis, or studies that reported colistin susceptibility testing methods other than micro-dilution.

2.3. Data Extraction and Data Collection

Name of the first author, date of publication, number of participants, length of time and location of the study, Klebsiella pneumoniae strain identified, and resistance to colistin and other antibiotics were used. Data were collected by three writers (L.I.U., F.A.A., and A.H.), while a fourth writer (A.A.R.) reviewed the data's validity. Figure 1 shows the flow chart of the literature screening process.

Figure 1. Flow chart of the literature screening process.

2.4. Quality Assessment

The revised Critical Appraisal Checklist developed by the Joanna Briggs Institute [20,21] in which disagreements are resolved by consensus. The checklist for each study required the reviewers to complete seven items, with question four having two possible answers. One point was awarded for each “Yes”. The final score for each research might fall between 0 and 8 (Table S1 in supplementary Document).

2.5. Meta-Analysis Approach

Every statistical analysis was conducted using OpenMeta (analyst) Software (Brown University, Providence, RI, USA). The Chi-Square test, often known as Cochran’s Q, was performed to establish whether or not the studies were heterogeneous before pooling the data. We used a random-effect model by the DelSimonian-Laird (DL) method to analyze data with substantial amounts of heterogeneity ($I^2 > 50\%$) [22]. The test developed by Begg was used to analyze publication bias. We determined the prevalence and 95% confidence interval by Jackson method of DelSimonian-Laird (DL) model for colistin resistance across counties and based on the source of the sample.
3. Results
3.1. Studies Selection

A total of 2873 articles were recovered from the initial search. Ten (10) studies [5,23–32] out of 2873 recovered met the predefined inclusion criteria and were included in the final analysis. Articles based on a review or case report were not considered. Moreover, studies that used methods other than micro-dilution for antibiotic susceptibility for colistin were excluded as micro-dilution is the only standard method with established breakpoints. Studies reporting different antibiotic resistance prevalence other than colistin with other classes of antibiotics were excluded from the study. The selection process and characteristics of each of the studies, including quality score, are shown in Figure 1 and Table S1 (supplementary file). The included studies were from seven (7) countries across four WHO regions: America, Eastern Mediterranean, South-East Asia, and Western Pacific, respectively. All of the included studies examined colistin resistance in *Klebsiella pneumoniae* isolates recovered from bloodstream infections.

3.2. Overall Pooled Colistin Resistance in *Klebsiella pneumoniae* from Bloodstream Infection in the Study

A total of 89 *Klebsiella pneumoniae* had colistin resistance from 2856 *Klebsiella pneumoniae* isolates from bloodstream infections from the ten (10) included studies. The pooled prevalence of colistin resistance was 3.1%, 95% CI (1.5–4.7%) with a heterogeneity value ($I^2$ of 84%), as shown in Figure 2. The funnel plot (Figure 3) with Egger’s regression asymmetry test ($p < 0.05$) and Kendall’s Tau test ($p = 0.382$). Figure 4 showed periodic pooled prevalence resistance of bacteremia *Klebsiella pneumoniae* from bloodstream infections, and a pooled colistin resistance of 2.89% (48/1661) was observed in isolates recovered in the year 2015 or before, a 2.95% (28/948) pooled colistin resistance was observed in *Klebsiella pneumoniae* isolates from bloodstream infections in the year 2016 to 2019, while a 12.90% (4/31) pooled colistin resistance was observed in *Klebsiella pneumoniae* isolates from bloodstream infections in the year 2020 and after.

3.3. Antibiotic Resistance Rate in the Studied *Klebsiella pneumoniae*

Since there was high heterogeneity ($I^2 > 50\%$) in the prevalence of antibiotic resistance of *Klebsiella pneumoniae* in the study of the 5 studies that had multi-drug resistant (MDR), a pooled MDR of 80.1%, 95% CI (65.0–95.2%) was observed, amikacin showed a 25.4%, 95% CI (8.0–42.7%) pooled resistance, ciprofloxacin showed a 45.3%, 95% CI (13.2–77.5%) pooled resistance from five studies, ertapenem, imipenem and meropenem showed a 44.4%, 95% CI (19.9–68.8%), 35.2%, 95% CI (18.9–51.5%) and 36.1%, 95% CI (19.6–52.5%) pooled resistance, respectively, while gentamicin and tigecycline showed 33.3%, 95% CI (7.4–59.2%)
and 5.1%, 95% CI (0.3–10.0%) pool resistance in the studied *Klebsiella pneumoniae* from bloodstream infections as illustrated in Table 1.

![Funnel plot](image1)

**Figure 3.** A funnel plot based on the Colistin Resistance of included studies evaluated publication bias.

![Colistin Resistance](image2)

**Figure 4.** Time Trend Meta-analysis of Colistin Resistance in *Klebsiella pneumoniae* from Blood Stream Infection by Year of Study.

**Table 1.** Pooled Antibiotic Resistance Rate in *Klebsiella pneumoniae* isolates from bloodstream infections.

| Antibiotic     | Number of Studies | n/N      | Resistance (%) | Lower Limit | Upper Limit |
|----------------|-------------------|----------|----------------|-------------|-------------|
| MDR            | 5                 | 235/357  | 80.1           | 65.0        | 95.2        |
| Amikacin       | 4                 | 121/1080 | 25.4           | 8.0         | 42.7        |
| Ciprofloxacin  | 5                 | 1372/1980| 45.3           | 13.2        | 77.5        |
| Ertapenem      | 3                 | 787/1800 | 44.4           | 19.9        | 68.8        |
| Gentamicin     | 4                 | 223/1080 | 33.3           | 7.4         | 59.2        |
| Imipenem       | 5                 | 818/1980 | 35.2           | 18.9        | 51.5        |
| Meropenem      | 6                 | 838/2144 | 36.1           | 19.6        | 52.5        |
| Tigercycline   | 3                 | 25/483   | 5.1            | 0.3         | 10.0        |

Keys: n = number of outcome, N = Total of number tested, CI = confidence interval, % = Percent.
3.4. Pooled Colistin Resistance Rate in the Studied Klebsiella pneumoniae from Bloodstream Infections by Country of Study and Isolates Sources

As shown in Table 2, *Klebsiella pneumoniae* bloodstream infection from Thailand showed the highest rate of resistance 19.2%, 95% CI (4.1–34.4%), Brazil followed this with a reported colistin resistance rate of 14.6%, 95% CI (4.6–24.6%). Isolates from Pakistan showed 12.9%, 95% CI (1.1–24.7%) colistin resistance, a 2.8%, 95% CI (1.4–6.1%), and 7.6%, 95% CI (3.9–19.0%) pooled colistin resistance was observed in bloodstream infection caused by *Klebsiella pneumoniae* from China and India, respectively. However, South Korea reported the least colistin resistance, 0.8%, 95% CI (0.2–1.6%) in *Klebsiella pneumoniae* isolates from bloodstream infections among countries that have reported colistin resistance using the established method.

Table 2. Prevalence of Colistin Resistance in *Klebsiella pneumoniae* isolates from bloodstream infections by Country Study.

| Country        | Study Period (year/s) | Number of Study | n/N   | Resistance (%) | 95% CI Lower Limit | 95% CI Upper Limit |
|----------------|-----------------------|-----------------|-------|----------------|-------------------|-------------------|
| Brazil         | 2010–2015             | 1               | 7/48  | 14.6           | 4.6               | 24.6              |
| China          | 2011–2019             | 3               | 15/483| 2.8            | 1.4               | 6.1               |
| India          | 2008–2019             | 2               | 48/1529| 7.6           | 3.9               | 19.0              |
| Pakistan       | 2021                  | 1               | 4/31  | 12.9           | 1.1               | 24.7              |
| Peru           | 2018                  | 1               | 5/36  | 13.9           | 2.6               | 15.2              |
| South Korea    | 2016–2017             | 1               | 5/597 | 0.8            | 0.2               | 1.6               |
| Thailand       | 2017–2018             | 1               | 5/26  | 19.2           | 4.1               | 34.4              |

Keys: n = number of outcomes, N = Total of number tested, CI = confidence interval, % = Percent.

Figure 5 shows the colistin resistance in *Klebsiella pneumoniae* from bloodstream infection by isolated sources. The *Klebsiella pneumoniae* recovered from the intensive care unit (ICU) showed a colistin resistance of 11.5% (9/78). Other sources showed 3.03% (80/2604) resistance.

4. Discussion

Multidrug-resistant gram-negative bacteria (MDR) threaten public health globally [33]. Among gram-negative bacteria, *Klebsiella pneumoniae* is one of the most common causes of
healthcare-associated infections (HALs) [34]. *Klebsiella pneumoniae* associated with healthcare is highly resistant to several antibiotics, especially carbapenems [35,36]. In the fight against carbapenem-resistant *Klebsiella pneumoniae*, colistin (polymyxin E) is now commonly used [37]. In the intensive care unit (ICU), patients with bloodstream infections caused by carbapenem-resistant *Klebsiella pneumoniae* have poorer outcomes, resulting in a rising mortality rate globally [37,38]. Therefore, it is essential to understand the antimicrobial resistance profile of *Klebsiella pneumoniae* from bloodstream infection to provide interventions, including those for infection prevention and control. The data from 2016 through 2022 were included in this comprehensive review and meta-analysis on colistin and other antibiotic resistance in *Klebsiella pneumoniae* from bloodstream infections.

Colistin usage was popular in the 1940s until it was found to be very harmful to the kidneys and the nervous system in the 1970s, which led to its removal from use as a systemic antibacterial treatment [39]. At the same time, drugs with less harmful side effects were readily accessible and efficient, but this was short-lived with the development of resistance to those new antibiotics. As a result of the proliferation of carbapenem-resistant Gram-negative bacteria, polymyxins have become increasingly used as a medicine of last resort [40]. Globally, the use of colistin almost quadrupled from 2006 to 2012 [39,40]. Our study recorded a pooled colistin resistance prevalence of 3.1% in *Klebsiella pneumoniae* from bloodstream infections. Our findings contradicted a 10% colistin resistance in *Klebsiella pneumoniae* found in a recent clinical study involving clinical samples other than blood culture [41]. Our review was focused on bloodstream-infected *Klebsiella pneumoniae* resistant to colistin, with only ten studies using the recommended method to test antibiotic susceptibility testing. There is a need to develop a surveillance system that will include quality laboratory processes using the CLSI and EUCAST recommended microdilution method for antibiotic susceptibility testing for colistin resistance.

The observation from this study showed that there is a need to advocate the use of the right method in clinical settings to ensure the right insight into the actual colistin resistance rate globally. Although several studies have been conducted on colistin resistance, as shown in a recent bibliometric study of published articles on colistin resistance by *Klebsiella pneumoniae*, the actual resistance rate was not determined due to the heterogeneity in methods [34].

The high colistin resistance observed in bloodstream *Klebsiella pneumoniae* isolates studied from 2020 (the COVID-19 pandemic years) compared to the pre-COVID-19 period could be attributed to possible high colistin usage in clinical settings during the pandemic to treat carbapenem-resistant *Klebsiella pneumoniae*. This hypothesis is worth investigating to determine if the COVID-19 pandemic caused an increased colistin administration in hospital settings. To support our assertion, a recent study [40] which reported a case series of carbapenem-resistant *Klebsiella pneumoniae* infection with COVID-19 and how it was managed, showed that colistin was used in the two cases with one survivor. Arteaga-Livias et al. [40] explored how colistin became an indispensable drug in patients with carbapenem-resistant *Klebsiella pneumoniae* and COVID-19 co-infections.

Due to our study’s high heterogeneity (Figures 2 and 3), the outcome cannot be generalized to the population; therefore, caution should be applied when interpreting the study result. We used the random effect model due to dissimilarities in the studies used to account for this concern.

Bloodstream infection is particularly of concern as this can result in high mortality rates, especially those caused by carbapenem and colistin resistance. Understanding colistin resistance is important because there are no newer drugs in the pipelines. As demonstrated by our study, the average multidrug-resistant (MDR) *Klebsiella pneumoniae* from bloodstream infection was over 70%. Moderate amikacin resistance was observed in the study. Amikacin is a drug of choice in treating multi-drug-resistant *Klebsiella pneumoniae*. The increased resistance in isolates that are not even carbapenem-resistant is a concern as this has caused increased use of carbapenems, making them develop resistance quickly.
after exposure. This resistance showed that antibiotic therapy options available for the clinician are becoming narrower as time passes.

Bloodstream infections due to *Klebsiella pneumoniae* from the intensive care unit were more colistin-resistant than non-ICU. This finding agrees with the recent study in the United States, where resistance rates of bacterial isolates from ICU and non-ICU patients were compared. Higher resistance rate was reported for pathogens from ICU patients [41]. High colistin resistance in the ICU could be attributed to the increased use of colistin in ICU patients, especially as high carbapenem-resistant *Klebsiella pneumoniae* has been reported in the ICU by several studies [41–43]. Most carbapenem-resistant *Klebsiella pneumoniae* are resistant to the most available antibiotics; as a result, colistin is usually used in some cases. It has been reported that some experimental drugs have been designed and used, while some are at different phases of a clinical trial [44–48].

Although the data reported in this meta-analysis is not distributed in all continents, this meta-analysis reemphasizes the reemergence of colistin resistance due to the increased use of colistin for therapeutic purposes in carbapenem resistance in *Klebsiella pneumoniae*. Moreover, this meta-analysis provides more robust results that can help researchers and policy makers understand the magnitudes of the problem of increased colistin resistance as seen in data from 2020 and beyond giving insights to design an actionable solution.

5. Limitation of the Study

The studies included in this study were highly heterogeneous, being from different geographical locations, social-economic differences and also the difference in health care systems, including antimicrobial resistance control policy. These, therefore, hamper the process of generalizing the outcome to the general population. There was insufficient data for correlational analysis as most studies reported epidemiological data with limited clinical outcomes information. Furthermore, data for analysis in some aspects of the study were inadequate. This inadequate data may have therefore impacted the actual possible situation in the general population. Most countries had no reports, as such distribution across continents was not done. This inadequate of distribution of colistin resistance data across continents was mostly affected by wrong AST methods being used by most countries.

6. Conclusions

This study is the first systematic review and meta-analysis that examines *Klebsiella pneumoniae* colistin resistance from bloodstream infection to the best of our knowledge. This study showed low colistin resistance in *Klebsiella pneumoniae* isolates from bloodstream infections. However, significant colistin resistance was observed in isolates collected from 2020 and beyond. Significant colistin resistance was also observed in *Klebsiella pneumoniae* isolates in bloodstream infections from ICU compared to those from non-ICUs. As a result, there is a need to institute colistin administration stewardship in the ICU in clinical settings. There is a need for proper surveillance of colistin resistance using the right methods to give better insight into it and better prepare policymakers and the scientific community to manage increased resistance. Due to colistin toxicity, using the right techniques for its susceptibility will ensure patients are not unduly exposed due to wrong AST. There are guidelines for correctly testing the sensitivity of bacteria to colistin. They must be respected; otherwise, the results of the AST must be disregarded.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/pathogens11101092/s1, Table S1: Basic characteristics and quality score of included studies. Table S2: The data used for this study.

**Author Contributions:** Study conceptualization—L.I.U., A.A.R., F.A.A. and N.S.U., data acquisition and curation—L.I.U., J.B.F., M.A.B., M.G., W.A.A., M.A.H., A.A.A., S.A.H., F.S.A., A.H., A.A.M., S.A., J.E. and I.U.; Formal analysis—L.I.U., J.E., I.U., I.M.O. and W.A.A. Writing original draft—L.I.U. and A.A.R., Writing—review and editing: All authors. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data used for this study is attached as Supplementary Table S2.

Acknowledgments: The authors thank King Abdulaziz City for Science and Technology (KACST) for supporting the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Nagvekar, V.; Sawant, S.; Amey, S. Prevalence of multidrug-resistant Gram-negative bacteria cases at admission in a multispeciality hospital. J. Glob. Antimicrob. Resist. 2020, 22, 457–461. [CrossRef] [PubMed]

2. Navon-Venezia, S.; Kondratyeva, K.; Carattoli, A. Klebsiella pneumoniae: A major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol. Rev. 2017, 41, 252–275. [CrossRef] [PubMed]

3. Kazi, M.; Drego, L.; Nikam, C.; Ajhani, K.; Soman, R.; Shetty, A.; Rodrigues, C. Molecular characterization of carbapenem-resistant Enterobacteriaceae at a tertiary care laboratory in Mumbai. Eur. J. Clin. Microbiol. Infect. Dis. 2015, 34, 467–472. [CrossRef] [PubMed]

4. Dixit, A.; Kumar, N.; Kumar, S.; Trigun, V. Antimicrobial Resistance: Progress in the Decade since Emergence of New Delhi Metallo-β-Lactamase in India. Indian J. Community Med. 2019, 44, 4–8. [CrossRef] [PubMed]

5. Gandra, S.; Mojica, N.; Klein, E.; Ashok, A.; Nerurkar, V.; Kumari, M.; Ramesh, U.; Dey, S.; Vadwai, V.; Das, B.R.; et al. Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008–2014. Int. J. Infect. Dis. 2016, 50, 75–82. [CrossRef]

6. Azam, M.; Gaind, R.; Yadav, G.; Sharma, A.; Upmanyu, K.; Jain, M.; Singh, R. Colistin Resistance Among Multiple Sequence Types of Klebsiella pneumoniae Is Associated With Diverse Resistance Mechanisms: A Report from India. Front. Microbiol. 2021, 12, 609840. [CrossRef]

7. Monaco, M.; Giani, T.; Mojica, N.; Klein, E.; Ashok, A.; Nerurkar, V.; Kumari, M.; Ramesh, U.; Dey, S.; Vadwai, V.; Das, B.R.; et al. Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008–2014. Eurosurveillance 2014, 19, 20939. [CrossRef] [PubMed]

8. Giacobbe, D.; Del Bono, V.; Trecarichi, E.; De Rosa, F.; De Giacomo, M.; Bartoloni, A.; Losito, A.; Corcione, S.; Bartoletti, M.; et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: Results from a multicenter case-control-control study. Clin. Microbiol. Infect. 2015, 21, 1106.e1–1106.e8. [CrossRef]

9. Hazrultan, G.; Karagöz, A. Emergence of carbapenemase-producing and colistin resistant Klebsiella pneumoniae ST101 high-risk clone in Turkey. Acta Microbiol. Immunol. Hung. 2020, 67, 216–221. [CrossRef]

10. Karmakar, S.; Lagou, S.; Pontikis, K.; Rapti, V.; Poulaoukou, G. “The Old” and the “New” antibiotics for MDR Gram-negative pathogens: For whom, when, and how. Front. Public Health 2019, 7, 151. [CrossRef]

11. Morris, S.; Cercoo, E. Trends, Epidemiology, and Management of Multi-Drug Resistant Gram-Negative Bacterial Infections in the Hospitalized Setting. Antibiot 2020, 9, 196. [CrossRef] [PubMed]

12. Nirwan, P.K.; Chatterjee, N.; Pratap, M.; Anthappa, S.; Jaggi, N. Mutations in the two component system (PhoPQ and PmrAB) in colistin-resistant Klebsiella pneumoniae from North Indian tertiary care hospital. J. Antimicrob. 2021, 74, 450–457. [CrossRef] [PubMed]

13. Veeraraghavan, B.; Shankar, C.; Venkatesan, M.; Raja, R.; Mani, D.; Lal, B.; Prakash, J.A.J.; Anandan, S.; Pragasam, A.K.; Walia, K.; et al. Molecular characterization of colistin-resistant Klebsiella pneumoniae & its clonal relationship among Indian isolates. Indian J. Med. Res. 2019, 149, 199–207. [CrossRef]

14. Goel, G.; Hmar, L.; De, M.S.; Bhattacharya, S.; Chandy, M. Colistin-Resistant Klebsiella pneumoniae: Report of a Cluster of 24 Cases from a New Oncology Center in Eastern India. Infect. Control Hosp. Epidemiol. 2014, 35, 1076–1077. [CrossRef]

15. Chew, K.L.; La MVan Lin, R.T.P.; Teo, J.W.P. Colistin and Polymyxin B Susceptibility Testing for Carbapenem-Resistant and mcr-Positive Enterobacteriaceae: Comparison of Sensititre, MicroScan, Vitek 2, and Etest with Broth Microdilution. J. Clin. Microbiol. 2017, 55, 2609–2616. [CrossRef]

16. Hindler, J.A.; Humphries, R.M. Colistin MIC Variability by Method for Contemporary Clinical Isolates of Multidrug-Resistant Gram-Negative Bacilli. J. Clin. Microbiol. 2013, 51, 1678–1684. [CrossRef]

17. Arroyo, L.A.; García-Curriel, A.; Pachón-Ibañez, M.E.; Llanos, A.C.; Ruiz, M.; Pachón, J.; Aznar, J. Reliability of the E-Test Method for Detection of Colistin Resistance in Clinical Isolates of Acinetobacter baumannii. J. Clin. Microbiol. 2005, 43, 903–905. [CrossRef]

18. Satlin, M.J.; Lewis, J.S.; Weinstein, M.P.; Patel, J.; Humphries, R.M.; Kahlmeter, G.; Giske, C.G.; Turnidge, J. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Clin. Infect. Dis. 2020, 71, E523–E529. [CrossRef]

19. Matuschek, E.; Åhman, J.; Webster, C.; Kahlmeter, G. Antimicrobial susceptibility testing of colistin—Evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Clin. Microbiol. Infect. 2018, 24, 865–870. [CrossRef]
20. Joanna Briggs Institute. Critical-Appraisal-Tools—Critical Appraisal Tools | JBI. 2022. Available online: https://jbi.global/critical-appraisal-tools (accessed on 25 May 2022).

21. Munn, Z.; Moola, S.; Ritiano, D.; Lisy, K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int. J. Health Policy Manag. 2014, 3, 123–128. [CrossRef]

22. Mantel, N.; Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. JNCI J. Natl. Cancer Inst. 1959, 22, 719–748. [PubMed]

23. Bir, R.; Gautam, H.; Arif, N.; Chakravarti, P.; Verma, J.; Banerjee, S.; Tyagi, S.; Mohapatra, S.; Sood, S.; Dhawan, B.; et al. Analysis of colistin resistance in carbapenem-resistant Enterobacteriales and XDR Klebsiella pneumoniae. Ther. Adv. Infect. Dis. 2022, 9, 20499361221080650. [CrossRef] [PubMed]

24. Imtiaz, W.; Syed, Z.; Rafaque, Z.; Andrews, S.C.; Dasti, J.I. Analysis of Antibiotic Resistance and Virulence Traits (Genetic and Phenotypic) in Klebsiella pneumoniae Clinical Isolates from Pakistan: Identification of Significant Levels of Carbapenem and Colistin Resistance. Infect. Drug Resist. 2021, 14, 227–236. [CrossRef] [PubMed]

25. Xiao, S.; Chen, T.; Wang, H.; Zeng, Q.; Chen, Q.; Yang, Z.; Han, L.; Chen, E. Drug Susceptibility and Molecular Epidemiology of Klebsiella pneumoniae Bloodstream Infection in ICU Patients in Shanghai, China. Front. Med. 2021, 8, 754944. [CrossRef]

26. Naomi-Matsuoka, A.; Vargas, M.; Yamae, B.; Soza, G.; Pons, M.J. Colistin resistance in multidrug-resistant Klebsiella pneumoniae strains at a perinatal maternal institute in Lima, Peru, 2015–2018. Rev. Peru. Med. Exp. Salud Publica 2020, 37, 716–720. [CrossRef]

27. Santimaleeworagun, W.; Thunyaharn, S.; Juntanawiwat, P.; Thongnoy, N.; Harindhanavudhi, S.; Nakeesathit, S.; Teschumroon, S. The prevalence of colistin-resistant gram-negative bacteria isolated from hospitalized patients with bacteremia. J. Appl. Pharm. Sci. 2020, 10, 56–59.

28. Boszczowski, I.; Salomão, M.C.; Moura, M.L.; Freire, M.P.; Guimarães, T.; Cury, A.P.; Rossi, F.; Rizek, C.F.; Martins, R.C.R.; Costa, S.F. Multidrug-resistant Klebsiella pneumoniae: Genetic diversity, mechanisms of resistance to polymyxins and clinical outcomes in a tertiary teaching hospital in Brazil. Rev. Inst. Med. Trop. São Paulo 2019, 61, e29. [CrossRef]

29. Zhang, F.; Li, Y.; Lv, Y.; Zheng, B.; Xue, F. Bacterial susceptibility in bloodstream infections: Results from China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2015–2016. J. Glob. Antimicrob. Resist. 2019, 17, 276–282. [CrossRef]

30. Dong, F.; Zhang, Y.; Yao, K.; Lu, J.; Guo, L.; Lyu, S.; Yang, Y.; Wang, Y.; Zheng, H.; Song, W.; et al. Epidemiology of Carbapenem-ResistantKlebsiella pneumoniaeBloodstream Infections in a Chinese Children’s Hospital: Predominance of New Delhi Metallo-β-Lactamase-1. Microb. Drug Resist. 2018, 24, 154–187. [CrossRef]

31. Yong, D.; Shin, H.B.; Kim, Y.K.; Cho, J.; Lee, W.G.; Ha, G.Y.; Choi, T.Y.; Jeong, S.H.; Lee, K.; Chong, Y.; et al. Increase in the Prevalence of Carbapenem-Resistant Acinetobacter Isolates and Ampicillin-Resistant Non-Typhoidal Salmonella Species in Korea: A KONSAR Study Conducted in 2011. Infect. Chemother. 2014, 46, 84–93. [CrossRef]

32. Lee, H.; Yoon, E.-J.; Kim, D.; Jeong, S.H.; Won, E.J.; Shin, J.H.; Kim, S.H.; Shin, K.S.; Kim, Y.A.; et al. Antimicrobial resistance of major clinical pathogens in South Korea, May 2016 to April 2017: First one-year report from Kor-GLASS. Eurosurveillance 2018, 23, 1800047. [CrossRef]

33. Nwabor, O.; Terboethakun, P.; Voravuthikunchai, S.; Chusri, S. A Bibliometric Meta-Analysis of Colistin Resistance in Klebsiella pneumoniae. Diseases 2021, 9, 44. [CrossRef] [PubMed]

34. Juan, C.-H.; Chuang, C.; Chen, C.-H.; Li, L.; Lin, Y.-T. Clinical characteristics, antimicrobial resistance and capsular types of community-acquired, healthcare-associated, and nosocomial Klebsiella pneumoniae bacteremia. Antimicrob. Resist. Infect. Control 2019, 8, 1. [CrossRef] [PubMed]

35. Khurana, S.; Bharatwaj, N.; Kumari, M.; Malhotra, R.; Mathur, P. Prevalence, etiology, and antibiotic resistance profiles of bacterial bloodstream infections in a tertiary care hospital in Northern India: A 4-year study. J. Lab. Physicians 2018, 10, 426–431. [CrossRef] [PubMed]

36. Saharan, Y.R.; Karuniawati, A.; Severin, J.A.; Verbrugh, H.A. Infections and antimicrobial resistance in intensive care units in lower-middle income countries: A scoping review. Antimicrob. Resist. Infect. Control 2021, 10, 22. [CrossRef]

37. Kadri, S.S.; Hohmann, S.F.; Orav, E.J.; Bonne, S.L.; Moffa, M.A.; Timpone, J.G.; Strich, J.R.; Palmore, T.; Christopher, K.B.; Varughese, C.; et al. Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections. Clin. Infect. Dis. 2015, 60, 154–79. [CrossRef] [PubMed]

38. Falagas, M.E.; Kasiakou, S.K.; Saravolatz, L.D. Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections. Clin. Infect. Dis. 2005, 40, 1333–1341. [CrossRef] [PubMed]

39. Karki, D.; Dhungel, B.; Bhandari, S.; Kunwar, A.; Joshi, P.R.; Shrestha, B.; Rijal, K.R.; Ghimire, P.; Banjara, M.R. Antibiotic resistance and detection of plasmid mediated colistin resistance mcr-1 gene among Escherichia coli and Klebsiella pneumoniae isolated from clinical samples. Gut Pathog. 2021, 13, 45. [CrossRef]

40. Arteaga-Livias, K.; Pinzas-Acosta, K.; Perez-Abad, L.; Panduro-Correa, V.; Rabaan, A.A.; Pecho-Silva, S.; Dámaso-Mata, B. A multidrug-resistant Klebsiella pneumoniae outbreak in a Peruvian hospital: Another threat from the COVID-19 pandemic. Infect. Control Hosp. Epidemiol. 2022, 43, 267–268. [CrossRef]

41. Sader, H.S.; Mendes, R.E.; Streit, J.M.; Carvalhaes, C.G.; Castanheira, M. Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018–2020). Diagn. Microbiol. Infect. Dis. 2022, 102, 115557. [CrossRef] [PubMed]

42. Ibrahim, M.E. High antimicrobial resistant rates among Gram-negative pathogens in intensive care units: A retrospective study at a tertiary care hospital in Southwest Saudi Arabia. Saudi Med. J. 2018, 39, 1035. [CrossRef] [PubMed]
43. Sommerstein, R.; Damonti, L.; Marschall, J.; Harbarth, S.; Gasser, M.; Kronenberg, A.; Buetti, N. Distribution of pathogens and antimicrobial resistance in ICU-bloodstream infections during hospitalization: A nationwide surveillance study. Sci. Rep. 2021, 11, 16876. [CrossRef]

44. Raineri, E.; Crema, L.; Zoppo, S.D.; Acquarolo, A.; Pan, A.; Carnevale, G.; Albertario, F.; Candiani, A. Rotation of antimicrobial therapy in the intensive care unit: Impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 2010, 29, 1015–1024. [CrossRef] [PubMed]

45. Petrosillo, N.; Taglietti, F.; Granata, G. Treatment Options for Colistin Resistant *Klebsiella pneumoniae*: Present and Future. J. Clin. Med. 2019, 8, 934. [CrossRef] [PubMed]

46. Ko¸sar, I.; Dinc, G.; Eren, E.; Aykemat, Y.; Doganay, M. Investigation of double carbapenem efficiency in experimental sepsis of colistin resistant *Klebsiella pneumoniae*. North. Clin. Istanb. 2020, 8, 113–118. [CrossRef] [PubMed]

47. Docobo-Pérez, F.; Nordmann, P.; Domínguez-Herrera, J.; López-Rojas, R.; Smani, Y.; Poirel, L.; Pachón, J. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of *Klebsiella pneumoniae* and Escherichia coli. Int. J. Antimicrob. Agents 2012, 39, 251–254. [CrossRef]

48. Shein, A.M.S.; Wannigama, D.L.; Higgins, P.G.; Hurst, C.; Abe, S.; Hongsing, P.; Chantaravisoot, N.; Saethang, T.; Luk-In, S.; Liao, T.; et al. Novel colistin-EDTA combination for successful eradication of colistin-resistant *Klebsiella pneumoniae* catheter-related biofilm infections. Sci. Rep. 2021, 11, 21676. [CrossRef]